Viveve Medical (VIVE) Receives Marketing Approval for Viveve System in Singapore

August 9, 2016 8:29 AM EDT
Get Alerts VIVE Hot Sheet
Trade VIVE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Viveve Medical, Inc. (Nasdaq: VIVE) announced that the company has received regulatory approval for marketing the Viveve System from the Health Science Authority in Singapore. In 2015, Viveve announced that it entered into an exclusive distribution partnership for the Viveve System with NeoAsia PTE, Ltd. ("NeoAsia"), a distributor of medical devices based in Singapore. The announcement of market approval in Singapore follows the recent announcement of regulatory approval of the Viveve System in South Korea.

"Asia represents a very important market and, we believe, a major commercial opportunity for Viveve. We have taken many steps to support rapid commercialization of the Viveve System in Asia, including establishing a relationship with our distribution partner, NeoAsia, in Singapore. The regulatory approvals for the Viveve System in Singapore and in South Korea are significant milestones in our efforts to make this clinically-proven treatment available to the millions of women throughout Asia and around the world who are living with vaginal laxity," said Patricia Scheller, chief executive officer of Viveve.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Comments

Add Your Comment